Assessment of the Birmingham vasculitis activity score in patients with MPO-ANCA-associated vasculitis: sub-analysis from a study by the Japanese Study Group for MPO-ANCA-associated vasculitis

References

• Jennette JC, Falk RJ. Clinical and pathological classification of ANCA-associated vasculitis: what are the controversies?. Clin Exp Immunol. 1995;101: 18–22.
   PubMedGoogle Scholar
• Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988;318: 1651–1657.
   PubMed Web of Science ®Google Scholar
• Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, Es LA, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet. 1985;1: 425–429.
   PubMedGoogle Scholar
• Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K, et al. Incidence of ANCA-associated primary renal vasculitis in Miyazaki prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol. 2006;1: 1016–1022.
   PubMed Web of Science ®Google Scholar
• Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87: 671–678.
   PubMed Web of Science ®Google Scholar
• Ozaki S, Nakabayashi K, Tomino Y, Koyama T. A prospective, open-labeled, and multi-center trial of standard protocols for MPO-ANCA-associated vasculitis by Japanese Study Group for MPO-ANCA-associated vasculitis (JMAAV). Annual report 2005 of the Research Group for Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan. 2006. p. 199–323.
   Google Scholar
• Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56: 87–96.
   PubMedGoogle Scholar
• Flossmann O, Bacon P, Groot K, Jayne D, Rasmussen N, Seo P, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66: 283–292.
   PubMed Web of Science ®Google Scholar
• Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2011;22: 394–404.
   PubMedGoogle Scholar
• Luqmani RA, Exley AR, Kitas GD, Bacon PA. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol. 1997;11: 423–446.
   PubMed Web of Science ®Google Scholar
• Luqmani R. Evaluation of vasculitis disease activity in Europe. Eur J Intern Med. 2001;12: 401–402.
   PubMedGoogle Scholar
• Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc. 1997;72: 737–747.
   PubMedGoogle Scholar
• Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52: 2461–2469.
   PubMedGoogle Scholar
• Benenson E, Fries JW, Heilig B, Pollok M, Rubbert A. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener’s granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol. 2005;24: 251–257.
   PubMed Web of Science ®Google Scholar
• Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg–Strauss syndrome. Ann Rheum Dis. 2004;63: 1649–1654.
   PubMed Web of Science ®Google Scholar
• Jayne DR, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349: 36–44.
   PubMed Web of Science ®Google Scholar
• Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000;93: 433–439.
   PubMed Web of Science ®Google Scholar
• Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004;15: 717–721.
   PubMed Web of Science ®Google Scholar
• Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener’s granulomatosis. Rheumatology (Oxford). 2004;43: 315–320.
   PubMed Web of Science ®Google Scholar
• Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Hello C. et al Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002;41: 1126–1132.
   PubMed Web of Science ®Google Scholar
• Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol. 2003;14: 440–447.
   PubMed Web of Science ®Google Scholar
• Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transpl. 2005;20: 2725–2732.
   PubMed Web of Science ®Google Scholar
• Gayraud M, Guillevin L, Toumelin P, Cohen P, Lhote F, Casassus P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001;44: 666–675.
   PubMed Web of Science ®Google Scholar
• Cruz BA, Ramanoelina J, Mahr A, Cohen P, Mouthon L, Cohen Y, et al. Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology (Oxford). 2003;42: 1183–1188.
   PubMed Web of Science ®Google Scholar
• Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM. 2005;98: 97–111.
   PubMed Web of Science ®Google Scholar
• Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener’s granulomatosis. Rheumatology (Oxford). 2002;41: 572–581.
   PubMed Web of Science ®Google Scholar
• Itabashi M, Takei T, Yabuki Y, Suzuki H, Ando M, Akamatsu M, et al. Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. Nephron Clin Pract. 2010;115: c21–c27.
   PubMedGoogle Scholar
• Suzuki Y, Takeda Y, Sato D, Kanaguchi Y, Tanaka Y, Kobayashi S, et al. Clinicoepidemiological manifestations of RPGN and ANCA-associated vasculitides: an 11-year retrospective hospital-based study in Japan. Mod Rheumatol. 2010;20: 54–62.
   PubMed Web of Science ®Google Scholar